8 results on '"Sanja Dacic"'
Search Results
2. Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go
- Author
-
Henry D. Tazelaar, Anja C. Roden, Alberto Cavazza, Jun Fukuoka, Mari Mino-Kenudson, Kirk D. Jones, Wendy A Cooper, Maxwell L. Smith, Thomas V. Colby, Lynette M. Sholl, Mary Beth Beasley, Sanja Dacic, Alain C. Borczuk, Lida P. Hariri, Annabelle Mahar, Richard Attanoos, Andrew Churg, Brandon T. Larsen, and Kevin O. Leslie
- Subjects
medicine.medical_specialty ,Biopsy ,MEDLINE ,Pathology and Forensic Medicine ,03 medical and health sciences ,Idiopathic pulmonary fibrosis ,0302 clinical medicine ,Usual interstitial pneumonia ,medicine ,Humans ,030212 general & internal medicine ,Pulmonary pathology ,Intensive care medicine ,Lung ,medicine.diagnostic_test ,business.industry ,Interstitial lung disease ,General Medicine ,Guideline ,respiratory system ,medicine.disease ,Idiopathic Pulmonary Fibrosis ,Pathologists ,Medical Laboratory Technology ,030228 respiratory system ,Practice Guidelines as Topic ,business ,Lung Diseases, Interstitial - Abstract
Context.—Accurate diagnosis of idiopathic pulmonary fibrosis (IPF) requires multidisciplinary diagnosis that includes clinical, radiologic, and often pathologic assessment. In 2018, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and the Latin American Thoracic Society (ATS/ERS/JRS/ALAT) and the Fleischner Society each published guidelines for the diagnosis of IPF, which include criteria for 4 categories of confidence of a histologic usual interstitial pneumonia (UIP) pattern.Objective.—To (1) identify the role of the guidelines in pathologic assessment of UIP; (2) analyze the 4 guideline categories, including potential areas of difficulty; and (3) determine steps the Pulmonary Pathology Society and the greater pulmonary pathology community can take to improve current guideline criteria and histopathologic diagnosis of interstitial lung disease.Data Sources.—Data were derived from the guidelines, published literature, and clinical experience.Conclusions.—Both guidelines provide pathologists with a tool to relay to the clinician the likelihood that a biopsy represents UIP, and serve as an adjunct, not a replacement, for traditional histologic diagnosis. There are multiple challenges with implementing the guidelines, including (1) lack of clarity on the quantity and quality of histologic findings required, (2) lack of recognition that histologic features cannot be assessed independently, and (3) lack of guidance on how pathologists should incorporate clinical and radiographic information. Current criteria for “probable UIP” and “indeterminate for UIP” hinder accurate reflection of the likelihood of IPF. These challenges highlight the need for further morphologic-based investigations in the field of pulmonary pathology.
- Published
- 2020
3. p16 Deletion in sarcomatoid tumors of the lung and pleura
- Author
-
Sanja Dacic, Philip T. Cagle, Timothy Craig Allen, Lucian R. Chirieac, Richard Attanoos, and Naobumi Tochigi
- Subjects
Adult ,Mesothelioma ,Pathology ,medicine.medical_specialty ,Solitary fibrous tumor ,Lung Neoplasms ,Pleural Neoplasms ,Locus (genetics) ,Pathology and Forensic Medicine ,medicine ,Biomarkers, Tumor ,Humans ,Cyclin-Dependent Kinase Inhibitor p16 ,P16 gene ,Lung ,medicine.diagnostic_test ,business.industry ,Genetic Alteration ,Sarcoma ,General Medicine ,respiratory system ,medicine.disease ,Prognosis ,respiratory tract diseases ,Neoplasm Proteins ,Medical Laboratory Technology ,medicine.anatomical_structure ,Cancer research ,business ,Gene Deletion ,Fluorescence in situ hybridization - Abstract
The diagnosis of sarcomatoid neoplasms of the lung and pleura can be challenging. Homozygous deletion of 9p21, the locus harboring the p16 gene, has been reported as the most common genetic alteration in malignant mesotheliomas that is of potential diagnostic and prognostic significance.To evaluate the frequency of 9p21 deletion by fluorescence in situ hybridization in the primary sarcomatoid neoplasms of the lung and pleura and to determine its potential diagnostic utility.Ninety-two sarcomatoid neoplasms of the lung and pleura (32 sarcomatoid mesotheliomas, 15 sarcomatoid carcinomas, 32 solitary fibrous tumors, and 13 high-grade sarcomas) were examined for 9p21 deletion by fluorescence in situ hybridization.Deletion of 9p21 was most frequently seen in malignant mesotheliomas (81%), followed by sarcomatoid carcinomas (53%), sarcomas (25%), and solitary fibrous tumors (12.5%). Malignant mesotheliomas showed mostly homozygous deletion, whereas sarcomatoid carcinomas showed either homozygous or hemizygous deletion. None of the sarcomas showed homozygous deletion. There was a trend toward more frequent occurrence of 9p21 deletion in recurrent solitary fibrous tumors, but this did not reach statistical difference.Deletion of 9p21 is common in sarcomatoid tumors of the lung and pleura. Despite statistically significant differences in the frequency of 9p21 deletion, and because of the large overlap among the study groups, this genetic abnormality cannot be used as a reliable diagnostic tool in the assessment of sarcomatoid lesions of the lung and pleura. A potential use of p16 deletion in predicting the biology of solitary fibrous tumors should be further explored.
- Published
- 2013
4. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group
- Author
-
Lucian R. Chirieac, Thomas Krausz, Leslie A. Litzky, Kelly J. Butnor, Nelson G. Ordóñez, Mary Beth Beasley, Victor L. Roggli, Allen M. Gown, Aliya N. Husain, Mark R. Wick, Richard Attanoos, Andrew Churg, Sanja Dacic, Alberto M. Marchevsky, Andrew G. Nicholson, Allen R. Gibbs, Samuel P. Hammar, Alain C. Borczuk, Philip T. Cagle, Thomas V. Colby, Françoise Galateau-Sallé, Armando E. Fraire, and William D. Travis
- Subjects
Mesothelioma ,Pathology ,medicine.medical_specialty ,Lung ,Lung Neoplasms ,business.industry ,Pleural Neoplasms ,Mesothelioma, Malignant ,General Medicine ,Adenocarcinoma ,medicine.disease ,Sarcomatoid Mesothelioma ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Medical Laboratory Technology ,Mesothelial hyperplasia ,medicine.anatomical_structure ,medicine ,Immunohistochemistry ,Humans ,Pleural Neoplasm ,Differential diagnosis ,business - Abstract
Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose.To provide updated practical guidelines for the pathologic diagnosis of MM.Pathologists involved in the International Mesothelioma Interest Group and others with an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks.There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. It is recommended that immunohistochemical markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.
- Published
- 2012
5. Lung carcinoma morphology or mutational profile: that is the question
- Author
-
Sanja Dacic
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Cell ,Adenocarcinoma of Lung ,Biology ,Adenocarcinoma ,medicine.disease_cause ,Small-cell carcinoma ,Pathology and Forensic Medicine ,Epidermal growth factor ,Internal medicine ,medicine ,Carcinoma ,Humans ,Mutation ,Lung ,General Medicine ,medicine.disease ,respiratory tract diseases ,ErbB Receptors ,Medical Laboratory Technology ,medicine.anatomical_structure ,Female ,KRAS - Abstract
Lung carcinoma represents a heterogenous group of cancers that was for decades simply viewed as small cell carcinoma versus non–small cell lung carcinoma (NSCLC) for diagnostic purposes. This was mainly influenced by the lack of specific therapy for various histologic types and variants of NSCLC. Histologic distinction between adenocarcinoma and other types of NSCLC, particularly squamous cell carcinoma, became important after several milestone reports of epidermal growth factor receptor–tyrosine kinase inhibitor (EGFRTKI) efficacy in lung adenocarcinomas were published. 1–3 Since these initial reports about clinicopathologic characteristics of responders to EGFR-TKIs, several studies have attempted to better define the morphology of adenocarcinomas occurring in patients with EGFR and KRAS mutations. Initial reports indicated that EGFR mutations were most frequently observed in bronchioloalveolar carcinomas. 4–6 However, studies that applied the strict
- Published
- 2011
6. Molecular diagnostics of lung carcinomas
- Author
-
Sanja Dacic
- Subjects
Pathology ,medicine.medical_specialty ,PubMed ,Lung ,Lung Neoplasms ,business.industry ,General Medicine ,Genes, erbB-1 ,Adenocarcinoma ,Molecular diagnostics ,medicine.disease ,Pathology and Forensic Medicine ,Medical Laboratory Technology ,medicine.anatomical_structure ,Molecular Diagnostic Techniques ,Mutation ,medicine ,Carcinoma ,Biomarkers, Tumor ,Humans ,Molecular Targeted Therapy ,business - Abstract
Context.—The development of targeted therapies in the treatment of lung carcinoma is a rapidly growing area that requires a precise histologic classification of lung carcinomas and the implementation into clinical practice of testing for predictive biomarkers of therapy response. Molecular testing has added another layer of complexity in the routine workup of rather limited diagnostic tumor tissue. Objective.—To review the most important lung carcinoma biomarkers predictive of response and to discuss proposed routine molecular testing in clinical practice. Data Sources.—PubMed (US National Library of Medicine)–available review articles, peer-reviewed original articles, and experience of the author. Conclusions.—Histologic profile, clinical characteristics, and mutational profile of lung carcinoma have all been reported as predictive factors of response to epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) and other targeted therapies. Recently published results of large clinical trials indicate that mutational profiling, particularly identification of activating epidermal growth factor receptor (EGFR) mutations, is the best predictor for EGFR-TKI response. Despite all these observations, molecular profiling of lung carcinomas has not been standardized or validated in clinical practice. Rapid development of targeted therapies will probably require molecular testing for a panel of mutations to identify molecular subtypes of non–small cell lung carcinomas that will benefit from new therapeutic approaches in personalized patient care.
- Published
- 2011
7. Revolution in lung cancer: new challenges for the surgical pathologist
- Author
-
Philip T. Cagle, Timothy C. Allen, Sanja Dacic, Mary Beth Beasley, Alain C. Borczuk, Lucian R. Chirieac, Rodolfo Laucirica, Jae Y. Ro, and Keith M. Kerr
- Subjects
Medical Laboratory Technology ,Lung Neoplasms ,Professional Role ,Pathology, Surgical ,Biomarkers, Tumor ,Humans ,General Medicine ,Molecular Targeted Therapy ,Adenocarcinoma ,Precision Medicine ,Pathology and Forensic Medicine - Abstract
Context—Traditionally, lung cancer has been viewed as an aggressive, relentlessly progressive disease with few treatment options and poor survival. The traditional role of the pathologist has been primarily to differentiate small cell carcinoma from non–small cell carcinoma on biopsy and cytology specimens and to stage non–small cell carcinomas that underwent resection. In recent years, our concepts of lung cancer have undergone a revolution, including (1) the advent of successful, new, molecular-targeted therapies for lung cancer, many of which are associated with specific histologic cell types and subtypes; (2) new observations on the natural history of lung cancer derived from ongoing high-resolution computed tomography screening studies and recent histologic findings; and (3) proposals to revise the classification of lung cancers, particularly adenocarcinomas, in part because of the first 2 developments. Objective—To summarize the important, new developments in lung cancer, emphasizing the role of the surgical pathologist in personalized care for patients with lung cancer. Data Sources—Information about the new developments in lung cancer was obtained from the peer-review medical literature and the authors' experiences. Conclusions—For decades, we have perceived lung cancer as a relentlessly aggressive and mostly incurable disease for which the surgical pathologist had a limited role. Today, surgical pathologists have an important and expanding role in the diagnosis and treatment of lung cancer, and it is essential to keep informed of new advances.
- Published
- 2011
8. Pulmonary preneoplasia
- Author
-
Sanja Dacic
- Subjects
Medical Laboratory Technology ,Lung Neoplasms ,Humans ,General Medicine ,Precancerous Conditions ,Pathology and Forensic Medicine ,Neoplasm Staging - Abstract
Context.—Improved screening techniques for lung cancer have resulted in detection of lesions that are considered to represent precursors of invasive lung carcinomas. These lesions may cause a diagnostic dilemma particularly on small biopsy or cytology specimens. Ancillary studies are usually not helpful, and diagnosis is based on morphology alone. Recognition of these lesions is very important to prevent potential diagnostic mistakes that may result in inadequate patient management. Future molecular studies may provide clinically useful diagnostic and prognostic gene markers. Objective.—To review currently proposed morphologic criteria for precursor lesions of non–small cell lung carcinomas including squamous dysplasias, atypical adenomatous hyperplasia, and diffuse idiopathic neuroendocrine cell hyperplasia. Major molecular abnormalities are briefly discussed. Data Sources.—Published literature and recent World Health Organization classification of lung tumors. Conclusions.—Practicing surgical pathologists must be familiar with morphology of recognized pulmonary preneoplastic lesions that are more frequently detected radiographically and subjected to diagnostic procedures. Future understanding of underlying molecular abnormalities associated with progression of these lesions into invasive lung carcinoma may result in a development of molecular assays with potential diagnostic and prognostic importance.
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.